About Adimab
Adimab is an antibody discovery and optimization platform, developing full-length human Immunoglobulin Gs.
Headquarters
Adimab, Lebanon
Founded
2007-05-01
Industry
Biotechnology, Collaboration, Health Care, Therapeutics
Last Funding Type
Series Unknown
Valuation
1
Total Funding
$45.48 million dollars
IPO Status
Private
Financial
Adimab is focused on the discovery and optimization of antibodies, particularly full-length human Immunoglobulin Gs. Relevant patents include the development of anti-coagulation factor XI antibodies, which inhibit blood coagulation and associated thrombosis, and the creation of rationally designed, synthetic antibody libraries that reflect the preimmune repertoire. These efforts highlight Adimab's commitment to advancing antibody technology through innovative library design and targeted therapeutic applications.
Funding Rounds
8
Number of Lead Investors
3
Total Funding Amount
$45.48 million dollars
Number of Investors
6